ClinicalTrials.gg
Active, not recruitingNCT04929210STARUpdated Nov 3, 2026

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

A Phase 4 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 240 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Updated Nov 3, 20262 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
411
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
4th of 14
411 · median 173
Started
2021
with 3 others
Phase 4
3 of 14
2 open now
Registered
6th of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 4, and was the 6th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Read the detailed description

PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) criteria at screening
  • Have active PsA as defined by: a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline and b) C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram/deciliter (mg/dL) at screening from the central laboratory, and despite previous non-biologic disease modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
  • Have magnetic resonance imaging (MRI)-confirmed PsA axial disease (positive MRI spine and/or sacroiliac [SI] joints, shown by a Spondyloarthritis Research Consortium of Canada [SPARCC] score of >= 3 in either the spine or the sacroiliac joints)
  • Have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4, and have a spinal pain score (on a visual analog scale [VAS]) of at least 4
  • Have active plaque psoriasis, with at least 1 psoriatic plaque of >= 2 centimeter (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis

Exclusion criteria

Exclusion Criteria:

  • Has known allergies, , or intolerance to guselkumab or its
  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing spondylitis (AS)/non-radiographic-axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received a Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other JAK inhibitor
  • Has received any systemic (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
411 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab and Placebo

    Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab SC.

    Drug: Guselkumab

  • Experimental
    Group 3: Placebo followed by Guselkumab

    Participants will receive matching placebo and will cross over to receive guselkumab SC.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Guselkumab will be administered as subcutaneous injection.

    Also known as: TREMFYA

  • DrugPlacebo

    Matching placebo will be administered as subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24

    BASDAI is a self-assessment tool that consists of 6 questions relating to 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. First 5 items were scored on a 10 centimeter (cm) visual analog scale (VAS) ranging from 0 equals to (=) none to 10=very severe. Quantitative morning stiffness was scored on a 10 cm VAS ranging from 0=0 hours to 10=2 or more hours. 2 scores for qualitative and quantitative morning stiffness were averaged, and total BASDAI score was average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change from Baseline in Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP) at Week 24

    The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the C-reactive protein (CRP) value. Selected cut-offs for improvement scores are: a change greater than or equal to (\>=) 1.1 units for "clinically important improvement" and a change \>= 2.0 units for "major improvement.

    Time frame: Baseline and Week 24

  2. Change from Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 24

    DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (milligram/deciliter \[mg/dL\], value less than \[\<\] lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), participant assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

    Time frame: Baseline and Week 24

  3. Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24

    HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline and Week 24

  4. Percentage of Participants with Investigator's Global Assessment (IGA) 0/1 Response at Week 24 among Participants with >= 3% Body Surface Area (BSA) Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    Percentage of participants with IGA 0/1 response at week 24 among the participants with \>= 3 percent (%) BSA psoriatic involvement and an IGA score of \>= 2 (mild) at baseline will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given timepoint. Overall lesions are graded for induration, erythema, and scaling using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 24

  5. Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Score for Magnetic Resonance Imaging (MRI) Sacroiliac (SI) Joints at Week 24

    Change from baseline in SPARCC score for MRI SI joints at week 24 among the participants with a positive MRI of the sacroiliac joints at baseline will be reported. SPARCC method focuses on the cartilaginous portion of the SI joint, and scores presence (score of 1) versus absence (score of 0) of bone marrow edema in each SI joint quadrant.

    Time frame: Baseline and Week 24

  6. Percentage of Participants who Achieve a >= 50 % Improvement from Baseline in BASDAI Score at Week 24

    Percentage of participants who achieve a \>= 50 % improvement from baseline in BASDAI score at week 24 will be reported.

    Time frame: Baseline and Week 24

  7. Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24

    Percentage of participants who achieve ASDAS clinically important improvement at week 24 will be reported.

    Time frame: Week 24

  8. Percentage of Participants who Achieve Ankylosing Spondylitis Activity Score (ASAS) 40 Response at Week 24

    Percentage of participants who achieve ASAS 40 response at Week 24 will be reported. ASAS 40 defined as improvement from baseline of \>= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Participant's global assessment (0 to 10 cm; 0=very well, 10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none, 10=very severe); no worsening at all from baseline in remaining domain.

    Time frame: Week 24

  9. Percentage of Participants who Achieve ASDAS Major Improvement at Week 24

    Percentage of participants who achieve ASDAS major improvement at Week 24 will be reported.

    Time frame: Week 24

  10. Change from Baseline in SPARCC Score for MRI Spine at Week 24

    Change from baseline in SPARCC score for MRI spine at week 24 among the participants with a positive MRI of the spine at baseline will be reported. The SPARCC scoring system for the spine scores the 6 discovertebral units considered by the reader as the most abnormal, and then separately assesses each quadrant of 3 adjacent sagittal slices, with additional points for "depth" and high "intensity" of the lesion.

    Time frame: Baseline and Week 24

  11. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 60 weeks

  12. Number of Participants with Serious Adverse Events (SAEs)

    A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Time frame: Up to 60 weeks

  13. Number of Participants with Reasonably Related AEs

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 60 weeks

  14. Number of Participants with AEs Leading to Discontinuation of Study Intervention

    Number of participants with AEs leading to discontinuation of study intervention will be reported.

    Time frame: Up to 60 weeks

  15. Number of Participants with Infections

    Number of participants with infections will be reported.

    Time frame: Up to 60 weeks

  16. Number of participants with Injection-Site Reactions

    Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.

    Time frame: Up to 60 weeks

  17. Number of Participants with Laboratory Abnormalities (Chemistry, Hematology) by Maximum Toxicity (Common Terminology Criteria for Adverse Events [CTCAE 5.0]) Grades

    Number of participants with laboratory abnormalities (chemistry, hematology) by maximum toxicity (CTCAE 5.0) grades will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.

    Time frame: Up to 60 weeks

  18. Serum Guselkumab Concentration Over Time

    Serum guselkumab concentration over time will be reported.

    Time frame: Up to 60 weeks

  19. Number of Participants with Antibodies to Guselkumab

    Number of participants with antibodies to guselkumab will be reported.

    Time frame: Up to 60 weeks

07

Study locations

240 sites

Showing the first 100 of 240 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Baraliakos X, Bird P, Deodhar A, Gladman DD, Helliwell PS, Poddubnyy D, Kavanaugh A, Ostergaard M, Soriano ER, Tam LS, Chakravarty SD, Leibowitz E, Gong C, Adelakun O, Xu S, Fuerst T, Saeed N, Landewe R, Mease PJ. Associations Between Clinical Characteristics and Magnetic Resonance Imaging of the Sacroiliac Joints and Spine: Exploratory Analysis of the Phase 4, Randomized, Placebo-Controlled STAR Study. J Psoriasis Psoriatic Arthritis. 2026 Oct 18:24755303261494534. doi: 10.1177/24755303261494534. Online ahead of print. PubMed 42898665 ↗
  • Kharouf F, Gladman DD. Advances in the management of psoriatic arthritis in adults. BMJ. 2024 Nov 21;387:e081860. doi: 10.1136/bmj-2024-081860. PubMed 39572047 ↗
  • Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Ostergaard M, Baraliakos X. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y. PubMed 36064592 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Apr 2027, 67 months after the start.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Aug 30, 2021
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 13, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed
Show 2 removed
  • Consultorios Médicos Dr. Catalán Pellet · Buenos Aires, Argentina
  • Hospital Militar Central Cir. My. Dr. Cosme Argerich · Buenos Aires, Argentina
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42898665 ↗
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42898665 ↗
    2 sites removed
    Show 2 removed
    • Consultorios Médicos Dr. Catalán Pellet · Buenos Aires, Argentina
    • Hospital Militar Central Cir. My. Dr. Cosme Argerich · Buenos Aires, Argentina
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04929210
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Aug 30, 2021
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 13, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion